This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 13 - 16, 2023
Marriott Marquis San DiegoLive In-Person Event: December 13 - 16, 2023
Book Now
Menu
Register
keyboard_arrow_right

MAIN CONFERENCE DEC. 16 - PST/PDT (Pacific Daylight, GMT-7)

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DEC. 16 - PST/PDT (Pacific Daylight, GMT-7)

search
On Demand
Fun Run on San Diego Harbor- Meet in Marriott Marquis Foyer
7:15am - 7:30am
Registration
Showing 2 of 2 Streams
7:30am - 8:00am
ALTHEA Libraries: Phage Display Libraries for Antibody Therapeutic Discovery and Development
  • Juan Carlos Almagro, PhD - Founder and CEO, GlobalBio, Inc.
7:30am - 8:00am
Next-Gen Antibody Engineering: Yeast-Derived Hypermutation and Machine Learning for GPCR Therapeutics
  • Alon Wellner, PhD - Vice President Biology and Co-Founder, Aureka Biotechnologies
Showing 2 of 2 Streams
8:10am - 8:15am
Co-Chairs’ Remarks
  • Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor in Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
8:15am - 8:45am
Engineering Antibodies for Agonism: From Fc to Fab
  • Mark Cragg, PhD - Chair in Experimental Cancer Biology, University of Southampton
8:45am - 9:15am
Fcγ-receptor-independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy
  • Stephan Fischer, Ph.D. - Founder CEO and CSO, IcanoMAB GmbH
9:15am - 9:45am
Anti-inflammatory Potential of PD-1 Agonist Antibodies
  • Akio Ohta, Ph.D. - Professor, Department of Immunology, FBRI at Kobe
9:45am - 10:30am
Networking Refreshment Break, Exhibit and Poster Viewing
8:10am - 8:15am
Co-Chairs’ Remarks
  • James Larrick, MD, PhD - Managing Director and Chief Medical Officer , Panorama Research Institute
  • Vaughn Smider, M.D., Ph.D. - Adjunct Professor, Molecular Medicine, The Scripps Research Institute
8:15am - 8:45am
The Use of Structure and Function to Make New Classes of Functional Antibodies to the TNF Superfamily: A Focus on TNFR2
  • Denise Faustman, M.D., Ph.D. - Associate Professor of Medicine, Harvard Medical School
8:45am - 9:15am
Brain Delivery of Biotherapeutics Using An Engineered Fc Transport Vehicle
  • Mihalis Kariolis, Ph.D. - Scientist, Antibody and Protein Engineering, Denali Therapeutics
9:15am - 9:45am
ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
  • Conor McGuire, PhD - Senior Scientist R&D, ArgenX
9:45am - 10:30am
Networking Refreshment Break, Exhibit and Poster Viewing
Showing 2 of 2 Streams
10:30am - 11:00am
Antibody Architectures and Interfaces - Nature’s Guide to Biotherapeutic Engineering
  • Greg Lazar, Ph.D. - Co-Founder and Chief Technology Officer, Dualitas Therapeutics
11:00am - 11:30am
Engineering Cell-type Selective Immunotherapies Via Cis-targeting
  • Kelly Moynihan, Ph.D. - Senior Director and Program Team Leader, Asher Biotherapeutics
11:30am - 12:00pm
Surrogate Cytokine Agonists (SCAs): Unlocking Natural and Novel Cytokine Signals with VHH-based Therapeutics
  • Patrick Lupardus, Ph.D. - VP, Research and Head of Protein Sciences, Synthekine
10:30am - 11:00am
Antibody/Protein Complexes Increase Inflammation in Neurodegenerative Disorders
  • Stuart Lipton, M.D., Ph.D - Professor, The Scripps Research institute
11:00am - 11:30am
Neuroimmune Interactions: From Basic Mechanisms to Novel CNS Therapeutics
  • Lu Shan, Ph.D. - Senior Director, Antibody Discovery and Protein Engineering, Alector
11:30am - 12:00pm
Development of Sex Selective ScFv Reagents as Diagnostics and Therapeutics for Alzheimer’s Disease
  • Michael Sierks - Professor, Chemical Engineering, Department of Chemical Engineering, Arizona State University
Showing 4 of 4 Streams
12:00pm - 12:30pm
Accelerating Early Discovery Through HTP and High-Speed Antibody Production
  • Lei Shi, Ph.D. - Senior Vice President, Biointron Biological
12:00pm - 12:30pm
Briefing Available for Sponsorship: Contact Blake Shuka at blake.shuka@informa.com
12:00pm - 12:30pm
Deep Learning Enables Exploration of Antibody Space on Unprecedented Scale
  • Yi Li - Vice President and Head of Antibody Discovery, XtalPi
12:00pm - 12:30pm
Unlocking the Potential of the Fc for More Effective Therapeutic Antibody Products
  • Amanda Gross, PhD - Associate Director, Immunology, SeromYx Systems
12:30pm - 2:10pm
Networking Luncheon, Last Chance for Exhibit and Poster Viewing
Showing 2 of 2 Streams
2:10pm - 2:15pm
Chairman’s Remarks
  • Mitchell Ho, PhD - Senior Investigator, Laboratory of Molecular Biology, NIH NCI
2:15pm - 2:45pm
Anti-mesothelin Adoptive Cell Therapy for Solid Tumors
  • Raffit Hassan, PhD - Head, Thoracic and Solid Tumor Immunotherapy Section, National Cancer Institute
2:45pm - 3:15pm
Towards a New Frontier in Medicine: In Vivo Engineering of Immune Cells
  • Adrian Bot, MD, PhD - Chief Scientific Officer and EVP, R&D, Capstan Therapeutics
3:15pm - 3:45pm
Protecting Allogeneic Transplants from Immune Rejection is the Key to Bringing Cell-based Therapies to Patients
  • Sonja Schrepfer - ., Sana Biotech
2:10pm - 2:15pm
Co-Chairs’ Remarks
  • Gregory Adams, PhD - Chief Scientific Officer, Elucida Oncology
  • Hossein Borghaei, D.O. - Director, Thoracic Medical Oncology, Fox Chase Cancer Center
2:15pm - 2:45pm
Reconsidering Some Commonly Held Beliefs About Antibody Drug Conjugates (ADCs)
  • Jamie Rich - Director, Technology, ADC Therapeutic Development, Zymeworks
2:45pm - 3:15pm
HER2 and EGFR Antibody- based Therapeutics for Lung Cancer: Lessons Learned
  • John Heymach, MD, PhD - Professor and Chair, Thoracic/Head and Neck Medical Oncology, MD Anderson
3:15pm - 3:45pm
Clinical Experience with An HER3 DXd ADC
  • Pasi Jänne, M.D., Ph.D - Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
3:45pm - 4:15pm
Networking Refreshment Break
Showing 2 of 2 Streams
4:15pm - 4:45pm
Targeting Intracellular Cancer Drivers using Peptide Centric (PC)-CAR T Cells
  • Mark Yarmarkovich, PhD - Assistant Professor, Department of Pathology, NYU Langone Health
4:45pm - 5:15pm
CAR Targeting Tumor Cells with HLA Loss
  • Agi Hamburger - Vice President, Discovery Research, A2 Biotherapeutics Inc
5:15pm - 5:45pm
Dual Specific CAR T Cells for Therapy of Solid Tumors
  • Richard Vile, Ph.D. - Consultant, Mayo Clinic, USA
4:15pm - 4:45pm
First in Human Studies with ELU001, an anti-Folate Receptor Alpha Targeted C'Dot Drug Conjugate
  • Gregory Adams, PhD - Chief Scientific Officer, Elucida Oncology
4:45pm - 5:15pm
Lessons Learned from 25 years of HER2 Targeting with Trastuzumab and ADCs Based upon Trastuzumab Such as TDM1 and Enhertu
  • Mark Pegram, MD - Professor of Medical Oncology, Stanford University School of Medicine
5:15pm - 5:45pm
FDA Perspectives on Clinical Translation and Review of Antibody-based Therapeutics
  • Harpreet Singh, MD - Director of the Division of Oncology 2, US FDA
5:45pm - 5:50pm
Close of Conference
MAIN CONFERENCE DEC. 15
Filter
Streams
Formats
Choose Day